Related Experiment Video
Updated: Aug 5, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025
Amanda B Payne1, Steph Battan-Wraith2, Sarah E Reese2
1National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Objective:
In 2023, 2 products, a long-acting monoclonal antibody (nirsevimab) and maternal respiratory syncytial virus (RSV) vaccination, were recommended in the United States to prevent severe RSV disease among infants in their first RSV season. Low uptake during the 2023 to 2024 RSV season limited effectiveness estimates. We estimated nirsevimab and maternal RSV vaccine effectiveness against RSV-associated emergency department (ED) encounters and hospitalization among US infants during the 2024 to 2025 RSV season, when uptake was higher.
Methods:
We used electronic health record data from 5 health care systems in test-negative analyses of ED encounters and hospitalizations with RSV-like illness during October 1, 2024 to March 31, 2025, among infants in their first RSV season. Nirsevimab and maternal RSV vaccine effectiveness were estimated by comparing RSV-positive with RSV-negative encounters with respect to immunization status in separate logistic regression models adjusted for age, race and ethnicity, sex, calendar day, and geographic region.
Results:
Among 3531 ED encounters and 470 hospitalizations included in the nirsevimab analyses, nirsevimab effectiveness against RSV-associated ED encounters and hospitalization was 62% (95% CI: 54-68) and 77% (95% CI: 61-87), respectively. Among 810 ED encounters and 187 hospitalizations included in the maternal RSV vaccine analyses, vaccine effectiveness against RSV-associated ED encounters and hospitalization was 49% (95% CI: 26-65) and 82% (95% CI: 54-93), respectively.
Conclusion:
Nirsevimab and maternal RSV vaccination were effective against RSV-associated ED encounters and hospitalization among infants in their first RSV season. As uptake increases and additional products are recommended, monitoring infant RSV immunization effectiveness remains important.
More Related Videos
Related Concept Videos
Respiratory Syncytial Virus Disease
Vaccinations
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Smallpox
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children

